Novo Nordisk shares have dropped ~50% since June 2024 due to poor trial results and other negative catalysts. See why I rate ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

In 2024, Novo Nordisk’s GLP-1 sales in diabetes increased by 21%, depicting greater patient outreach and market capture by its GLP-1 products. Novo Nordisk continues to be the global market ...

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.

Behind the Ozempic and Wegovy drugs to treat diabetes and weight loss, Novo Nordisk became Europe's ... We sell different types of products and services to both investment professionals and ...

U.S. compounding pharmacies have been allowed to make legal copies of Novo's Wegovy and diabetes ... that Novo Nordisk analysis had detected "impurities and even banned products" in some ...

After a distinguished career of 28 years with Novo Nordisk, hereof seven years as executive vice president of Commercial Strategy & Corporate Affairs, Camilla Sylvest has decided to leave the company.

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...

The issuer is solely responsible for the content of this announcement.